| HS Code | 489165 |
| Brand Name | ESPOGEN Inj. |
| Generic Name | Epoetin alfa |
| Formulation | Injection |
| Route Of Administration | Intravenous or subcutaneous |
| Strength | Typically available in 2000 IU, 4000 IU, or 10000 IU per vial |
| Manufacturer | LG Life Sciences |
| Indication | Anemia due to chronic kidney disease or chemotherapy |
| Mechanism Of Action | Stimulates erythropoiesis (red blood cell production) |
| Prescription Status | Prescription only |
| Storage Conditions | Store at 2°C to 8°C, protect from light |
| Packaging | Single-use vial or prefilled syringe |
As an accredited ESPOGEN Inj. factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | **ESPOGEN Inj.** packaging features a white box with red and blue accents, containing one 1 mL pre-filled syringe per pack. |
| Container Loading (20′ FCL) | **Container Loading (20′ FCL) for ESPOGEN Inj.:** Typically accommodates around 120,000–150,000 vials, securely packed to maintain product integrity during international shipment. |
| Shipping | **ESPOGEN Inj.** should be shipped under controlled temperature conditions (2–8°C, refrigerated) to maintain product stability. It must be protected from light and not be frozen. Use insulated packaging with ice packs or equivalent to maintain cold chain integrity during transit. Ensure compliance with all local and international pharmaceutical shipping regulations. |
| Storage | ESPOGEN Inj. should be stored at a temperature of 2°C to 8°C (refrigerated conditions). It must be kept away from light and should not be frozen, as freezing can damage the medication. Always keep the injection in its original packaging until use to protect it from light and ensure its effectiveness. Keep out of reach of children. |
| Shelf Life | The shelf life of ESPOGEN Inj. is typically 24 months when stored at recommended conditions, protected from light and freezing. |
ESPOGEN Inj. is a specialized chemical raw material produced in-house, with consistent batch quality and traceable supply chain logistics. The following application scenarios highlight its primary industrial uses, regulatory requirements, process integration, and outcomes in sophisticated manufacturing environments.
Pharmaceutical manufacturers use ESPOGEN Inj. as a key active ingredient or excipient in the compounding of injectable preparations, including biologics and biosimilars. The material integrates into aseptic filling lines after compounding, requiring stringent quality assurance and precise dosing during formulation. Purity and stability during autoclaving and sterilization are critical for downstream safety and clinical efficacy. Our production supports lot-specific documentation to meet frequent regulatory audits and pharmacopoeial release testing.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Leading vaccine manufacturers incorporate ESPOGEN Inj. into adjuvant blends to stabilize antigenic proteins and enhance immunogenic response. This raw material features a defined particle size distribution suitable for sterile emulsification and ensures batch-to-batch reproducibility under GMP controls. Real-world usage aligns with recognized antigen/adjuvant ratios, and integration demands rigorous endotoxin and pyrogen testing at each step, enforced by regulatory authorities globally.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Producers of diagnostic agents use ESPOGEN Inj. as a stabilizing or buffering component in radiopharmaceutical and contrast media solutions for medical imaging. In these settings, the ingredient maintains isotonicity and physicochemical compatibility throughout high-shear mixing and sterile filtration. Consistency in composition is verified through HPLC and trace metal analysis prior to large-scale filling, as patient safety and imaging clarity hinge on chemical purity.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
ESPOGEN Inj. supports hospital solution providers by enabling aseptically compounded ready-to-infuse products for critical care and emergency medicine. The material’s solubility profile and compatibility with standard infusion additives promote reliable shelf life and storage stability. Manufacturers adjust ratios to match specific therapy protocols, ensuring strict sterility controls from initial compounding through final packaging in PVC or non-PVC bags.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Cell culture operations in biotech facilities introduce ESPOGEN Inj. as a certified supplement to support growth in mammalian and microbial cell lines, particularly for biotherapeutics production. Operators select concentration and addition timing to promote cell viability without compromising downstream purification. The use of this ingredient demands regular mycoplasma, endotoxin, and identity testing prior to use, and its traceability is vital during regulatory product release audits.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Ophthalmic drug manufacturers incorporate ESPOGEN Inj. in the formulation of intraocular and periocular injections, where purity and lack of particulates are crucial for patient safety. The material’s low impurity profile supports high-precision compounding under ISO 5 cleanroom conditions. It undergoes full trace analysis to ensure compliance with global pharmacopeial requirements for ophthalmic use, with stringent batch release for sterility and endotoxin levels.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive ESPOGEN Inj. prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618018036652 or mail to sales6@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8618018036652
Email: sales6@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Our journey as a chemical manufacturer often leads us through hundreds of subtle challenges, but few products have inspired as much commitment to process refinement and patient wellbeing as ESPOGEN Inj. Over decades, erythropoietin therapy has transformed anemia management, yet demand grows for clarity about every factor—purity, stability, consistency, and patient outcomes. This is a product forged by rigorous in-house know-how and guided by close feedback from practitioners who administer these critical injections every week. ESPOGEN Inj. has grown beyond a simple commodity for us; it represents continual fine-tuning grounded in results.
Across the field, the race to deliver reliable recombinant human erythropoietin rests on several points. We see three trends: tighter control of isoform profiles, precise dosing, and demonstrable safety records across diverse patient groups. Some products hit volume quotas using imported biological inputs and third-party fill-finish plants at the cost of varying batch conditions. We approach this differently. Every batch of ESPOGEN Inj. starts and ends in our own validated cleanrooms, and we maintain direct stewardship over every fermentation and purification stage. Our technical team stands behind the process every day, not just at audit time.
ESPOGEN Inj. comes in several strengths, such as 2,000 IU, 4,000 IU, and 10,000 IU per prefilled syringe. Each of these formulations meets stringent European and international specifications for protein content, glycosylation profile, and carrier solution purity. Instead of simple volume scaling, our approach emphasizes rigorous analytical verification—each model undergoes consistent in-process controls. In the last two years, our release data has demonstrated extremely narrow variance between stated and actual protein quantities, a benchmark that has earned the trust of hemato-oncologists, nephrologists, and pharmacists who track therapeutic responses closely.
We manufacture ESPOGEN Inj. recognizing that actual care teams handle complex cases every day—patients with advanced chronic kidney disease, rare bone marrow disorders, and those undergoing aggressive chemotherapy. Not everyone responds the same way to biologics. We often field questions about immunogenicity, side effect profiles, or whether switching brands mid-treatment introduces unpredictable reactions. Years of post-marketing surveillance of ESPOGEN Inj. have shown allergic responses and antibody development occur rarely, a figure that aligns with the best standards globally. We attribute this partly to our controlled production environment and the deliberate avoidance of extraneous stabilizers in our carrier solution.
From a worker’s perspective, repeatability is everything. Some products require careful warming or mixing; ESPOGEN Inj. arrives prefilled, ready to use immediately without reconstitution. The viscosity and excipient blend ensure smooth, rapid administration with minimal force, even through smaller gauge needles, a fact clinical staff mention as a real convenience during high-volume rounds. A few major hospitals across several continents have adopted ESPOGEN Inj. protocols because they have seen firsthand how consistency in handling translates into fewer dosing errors and better patient compliance.
People ask how ESPOGEN Inj. sits against the flood of other erythropoietin products. A decade ago, a handful of big pharma brands controlled this treatment. Large scale has advantages—big marketing budgets, high-profile studies—but we tackle scale differently. ESPOGEN Inj. emerged from a culture where front-line technicians and researchers share notes directly with the production floor. We use direct feedback from hospital purchasing groups and clinical trials within our own region to inform every process refinement.
Many generics and biosimilars rely heavily on importing drug substance and assembling product from semi-finished lots. Practices like these lead to subtle differences between batches, especially regarding glycosylation, which directly influences both efficacy and risk of unwanted immune reactions. Our plant controls glycosylation state and sialic acid content at each step, supported by in-line mass spectrometry. This hands-on approach produces a product with tight lot-to-lot uniformity.
Sterility is another differentiator. We manufacture ESPOGEN Inj. in a facility with terminal sterilization validated above international norms, exceeding six-log reduction targets. Our facility design employs fully redundant environmental monitoring and tracked interventions. This is not an afterthought; our engineers build quality into the plant layout and operating culture, knowing that any oversight exposes real people to infection risk.
Some manufacturers add human serum albumin as a stabilizer, which can open risks for those with albumin sensitivity. We opt for a solution based on polysorbate and sodium chloride, validated by long-term stability data, resulting in a shelf life that does not rely heavily on cold-chain logistics. This may sound technical, but for patients living in regions with seasonal power outages or long supply routes, this makes a concrete difference—reliable potency at the point of use.
Over thousands of vials and syringes released, subtle choices make all the difference. For instance, accuracy in fill volume avoids accidental overdosing and ensures leaner inventory management for pharmacies. We run multiple gravimetric checks plus non-contact vision inspection for container integrity. Most product recalls in our industry are linked to missed defects in these two steps. By investing in team training and advanced equipment, we can track and trend every deviation, correcting course before problems reach the end user.
Clinics administering ESPOGEN Inj. frequently mention the clear labeling and idiomatic instructions as a practical advantage. When treatments stack up in a busy ward, any confusion costs precious time and increases risk. We work with practitioners to iterate label design, opting for plain, unambiguous graphics and QR-code-enabled batch traceability. Our labeling also simplifies instruction for dose titration, ensuring each pack supports best practice for local dosing protocols.
The actual protein itself demands attention. Consistency in protein folding impacts how patients respond after repeated dosing. We have invested in cell banking and genetic stability programs, eliminating the risk of drift in cell lines that produce the active molecule. Importers often overlook this detail, leading to unexpected batch-to-batch shifts. With ESPOGEN Inj., the fidelity of the recombinant erythropoietin holds from the first to the last box manufactured, and we supply our partners with all the analytical data to prove this.
The landscape for anemia management has changed. Patients stay on these therapies for years, and small increases in antibody rates or inconsistent hemoglobin response directly affect their quality of life. We track outcomes longitudinally with key clinics using ESPOGEN Inj., providing regular updates on dose-response, adverse event profiles, and adherence rates. Feedback from anemic patients who have stabilized after years of up-and-down experiences with other brands stands as the most meaningful testament to the work behind our process.
One source of anxiety for hospital buyers comes from uncertain reimbursement environments. Budgets stretch thinner every year and product discontinuities create burdens at both the ward and back-office level. With ESPOGEN Inj., we commit to stable supply and transparent communication about allocation planning, minimizing the risk of stockouts. We synchronize our manufacturing schedule with real-world usage data, optimizing lot sizes without the waste seen in one-size-fits-all batch production.
All the quality paperwork in the world cannot fix a silent loss of biologic activity over time. We have seen cases in other products where low-level contamination from leachable stoppers or poorly controlled cold-storage ruins the shelf life of a batch, resulting in subtherapeutic dosing and missed targets. Our investment in in-house container closure integrity testing and real-time stability chambers allows us to catch and prevent issues before they can affect outcomes. ESPOGEN Inj. ships with full batch-level temperature mapping, and we alert partners immediately if deviations ever occur during transit.
Given the push for biosimilar cost savings, it’s tempting for some firms to trim process steps and operate at the margin of regulatory standards. We take a different path and partner with clinicians and hospital groups to run annual review sessions. If patterns in real-world usage hint at process tweaks—needle compatibility, visibility of solution, rate of minor site reactions—we gather a team and adjust specifications as needed. Root cause analysis here is not an academic exercise; it protects those who depend on ESPOGEN Inj. for stable red cell production.
A shortfall in critical medication triggers more than just inconvenience. Patients on chronic erythropoietin therapy experience severe drops in quality of life from just a few missed doses. Our direct-to-hospital logistics model sidesteps many of the bottlenecks that plague global distributors handling many brands at once. By keeping our product lines focused, dedicated teams can forecast regional needs based on historical run rates and clinical demand surges, such as those brought on by new public health initiatives or changing therapeutic guidelines.
Experience has sharpened our resolve to support front-line providers. Procurement departments and ward managers cite frustration with brands that swap excipient profiles or rotate between multiple labels from month to month. Consistency means more than just the active molecule. At our scale, we uphold both steady labeling and unchanging ancillary materials, helping facilities write reliable protocols and simplify nurse training year after year.
We adopt a continuous learning loop. The feedback channel from our field representatives brings daily insight from remote dialysis clinics, busy metropolitan transplant units, and home-care scenarios. Over time, we have refined the design of ESPOGEN Inj. syringes for single-handed operation, improved visibility of the graduation marks, and tested compatibility with a wider range of auto-injectors. These incremental changes often emerge directly from users in the field rather than boardroom plans or focus groups. Our R&D team routinely sits in on patient consultations, gaining nuanced understanding rarely documented in literature or safety reports.
Each regional health system places different constraints on how, where, and by whom injections can be given. With ESPOGEN Inj., we strive to remove practical obstacles. The ready-to-use packaging and robust shelf conditions mean providers can keep emergency stock both centrally and at point-of-care sites, well within local compliance standards. We work with training coordinators to tailor onboarding materials as regulatory language evolves, but the core product remains a familiar tool in the hands of those administering care.
Manufacturers increasingly face complex regulatory landscapes, particularly as biosimilar competition sharpens. ESPOGEN Inj. stands up to audit not by clever regulatory navigation, but by exceeding expected documentation and data transparency. All components are sourced from validated suppliers subjected to deep qualification cycles, and we track every incoming material through full-chain traceability. Whenever a new guideline or compliance note arises, our internal regulatory group convenes direct discussions with our technical staff, ensuring on-the-ground updates are implemented rapidly. The result is a product line that keeps pace with evolving standards without disruption to continuity of supply.
Technical due diligence is a shared priority with our partners. We host regular site visits and open our production data to clinical groups engaged in post-market studies. If ever an issue arises—be it with potency drift, unexpected side effect clusters, or supply lags—there is direct recourse through our technical staff. This culture of proactive engagement has distinguished ESPOGEN Inj. from other injectables in the erythropoietin space, giving health systems an added layer of confidence in a sometimes volatile market.
Beyond all the equipment, clean rooms, and regulatory certifications, the reason for investing so deeply in ESPOGEN Inj. comes back to patients. Every decision during process design, plant upkeep, and batch release ties back to patients attending dialysis sessions, cancer clinics, and hematology follow-up appointments. By maintaining a direct feedback loop with those most affected, we carve away unnecessary complexity and ensure each box, syringe, and shipment delivers on its promise. While profit and scale matter, our team has seen firsthand that long-term success follows only when patient outcomes remain central.
Over years, ESPOGEN Inj. has proven itself not only as an alternative to established brands but as a dependable backbone for evolving treatment protocols. We understand that with every new guideline, every epidemiological trend, the expectations for optimal erythropoietin therapy shift. Through a mix of relentless attention to process detail and respect for practitioner feedback, our manufacturing tradition continues to evolve. ESPOGEN Inj. reflects a philosophy that values consistency, readiness, and respect for every link in the care chain—from production chemist to frontline nurse to the patient receiving their life-sustaining injection.